SANTA ANA, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that an abstract highlighting key data from a Phase I SNK01 study in Non-Small Cell Lung Cancer (NSCLC) has been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10 – 14, 2021, in Washington, D.C.
SANTA ANA, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that an abstract highlighting key data from a Phase I SNK01 study in Non-Small Cell Lung Cancer (NSCLC) has been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10 – 14, 2021, in Washington, D.C.
NKMax, a biotechnology company, announced the expansion of its clinical trial and supply agreement with Merck KGaA, Darmstadt, Germany to conduct a phase I/IIa open-label, single-center trial evaluating the safety and anti-tumor activity of SNK01 (autologous natural killer cells) in combination with either gemcitabine/carboplatin or gemcitabine/carboplatin plus cetuximab (Erbitux) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after prior tyrosine kinase inhibitor (TKI) therapy.
SEOUL, South Korea, April 13, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, announced the expansion of its clinical trial and supply agreement with Merck KGaA, Darmstadt, Germany to conduct a Phase I/IIa open-label, single-center trial evaluating the safety and anti-tumor activity of SNK01 (autologous natural killer cells) in combination with either gemcitabine/carboplatin or gemcitabine/carboplatin plus cetuximab (ERBITUX®)* in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after prior tyrosine kinase inhibitor (TKI) therapy. Preliminary in vitro data from an NKMax study suggested that EGFR-TKI resistant NSCLC cells highly express EGFR and are more efficiently killed by SNK01 in the presence of cetuximab through antibody-dependent cellular cytotoxicity (ADCC). Dr. Jae-Cheol Lee, M.D., Ph.D. from the Department of Oncology and Lung Cancer Center at Asan Medical Center, Seoul, Korea will be acting as principal investigator. This study was approved by Korea’s regulatory agency, MFDS, earlier this year as well as by the Asan Hospital IRB. The first patient will soon be enrolled.
SANTA ANA, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that it has changed its corporate name to NKGen Biotech, Inc., which the Company believes best reflects its mission and strategic focus. The name change is effective immediately.
Heidelberg, Germany and Santa Ana, Calif., March 31, 2021 – Affimed N.V. (NASDAQ: AFMD), a clinical-stage immuno-oncology company, and NKMax America Inc., a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) cleared an investigational new drug application (IND) for an Affimed and NKMax America co-sponsored Phase 1/2a dose escalation and expansion study in which the two companies will investigate the combination of AFM24, an EGFR/CD16A innate cell engager (ICE®), and SNK-01, an autologous NK-cell product, in patients suffering from tumors known to express EGFR. The combination represents a novel approach to exploring innate immunity-based therapeutics to treat patients with solid tumors who failed conventional therapy with the aim to improve outcomes for high-medical need patient populations.
NKMax America, a biotechnology company harnessing the power of the body's innate immune system through the development of Natural Killer (NK) cell therapies, today announced that the FDA has granted permission to amend its existing Phase I trial (NCT03941262) to add a new cohort of up to 18 patients to be treated with SNK01 in combination with either Pembrolizumab or Avelumab, two established checkpoint inhibitors.
SANTA ANA, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for SNK01 in combination with trastuzumab (Herceptin) or cetuximab (Erbitux) for the treatment of advanced/metastatic HER2- or EGFR- expressing cancers.